Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Niue Health Report.
Press releases published on September 5, 2025
Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
GlobeNewswire
·
September 5, 2025
MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence …
Healthinsurance.org: 5 ways to prepare now for Marketplace open enrollment
GlobeNewswire
·
September 5, 2025
Minneapolis, MN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- With Marketplace enrollees facing new documentation requirements and potentially large premium increases, now is the time to prepare for enrolling in 2026 coverage. According to healthinsurance.org, …
WellSpan announces changes to further enhance the safety and security of its facilities
GlobeNewswire
·
September 5, 2025
York, Pa., Sept. 05, 2025 (GLOBE NEWSWIRE) -- In support of its commitment to patient and team member safety, WellSpan Health today announced plans to further enhance security in its facilities, including increased weapons detection at entrances to its …
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
GlobeNewswire
·
September 5, 2025
SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted …
MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer
GlobeNewswire
·
September 5, 2025
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage …
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
GlobeNewswire
·
September 5, 2025
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and …
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
GlobeNewswire
·
September 5, 2025
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward Phase 2 IND …
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
GlobeNewswire
·
September 5, 2025
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod …
Safety Shot Appoints BONK Core Contributor Mitchell Rudy (Nom) to Board of Directors
GlobeNewswire
·
September 5, 2025
Transition Marks Next Phase in Company’s Strategic Integration with the Digital Asset Ecosystem SCOTTSDALE, AZ, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT), a company evolving to bridge the gap between traditional public markets and …
Tiziana Life Sciences Announces Purchase of Shares by Chairman
GlobeNewswire
·
September 5, 2025
BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
24/7 Market News: Kraig Labs Fibers are 5X Stronger Than Steel, Tougher than Kevlar, and Biodegradable
GlobeNewswire
·
September 5, 2025
DENVER, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and insights, reports that Kraig Biocraft Laboratories (OTCQB: KBLB)(“Kraig Labs” or “the Company”), the …
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 5, 2025
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards …
electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board
GlobeNewswire
·
September 5, 2025
ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has …
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 5, 2025
DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of …
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
GlobeNewswire
·
September 5, 2025
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were …
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
GlobeNewswire
·
September 5, 2025
KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological …
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
GlobeNewswire
·
September 5, 2025
EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 5, 2025
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on …
Theratechnologies annonce la disponibilité d’EGRIFTA WR (MC) (tésamoréline) pour injection pour la réduction de l’excès de graisse abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie
GlobeNewswire
·
September 5, 2025
EGRIFTA WRMC offre la commodité d’une reconstitution hebdomadaire et d’un volume d’injection quotidien réduit, comparativement à EGRIFTA SVMD Les pharmacies spécialisées commandent désormais EGRIFTA WRMC pour exécuter les ordonnances MONTRÉAL, 05 sept. …
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
GlobeNewswire
·
September 5, 2025
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 has a manageable …